At CureDuchenne we understand that when families are affected by a disease with no cure such as Duchenne muscular dystrophy, finding a sense of community is important. We are pleased […]
Today, PTC Therapeutics hosted a call for the Duchenne community to announce pricing and services for their launch of EMFLAZA, the commercial name for deflazacort. The announced price will be […]
Mother’s Day is a reminder to love our moms a little extra and be thankful for all that they do for us. For boys with Duchenne, it’s a reminder of […]
May 8, 2017 Dear Duchenne Families, Today we shared our plans for the launch of EMFLAZA™ (deflazacort), the first FDA-approved corticosteroid for Duchenne muscular dystrophy patients age 5 and […]
CureDuchenne is pleased to see the positive preliminary data from Capricor Therapeutics on their HOPE clinical trial in Duchenne muscular dystrophy. CureDuchenne Ventures helped fund this clinical trial to address […]
April 20, 2017 Dear Duchenne Community, Today we announced that we have completed our acquisition of Emflaza™ (deflazacort), the first FDA-approved, anti-inflammatory therapy for Duchenne Muscular Dystrophy (DMD) patients […]
NVC Consulting, a market research firm, is looking for patients and caregivers to participate in a paid market research study regarding the treatment of patients with Duchenne Muscular Dystrophy on […]
Physical Therapist Elina Gonzalez’s intuition has been a driving force in her career. During one of her early cases, a child presented signs of muscle weakness and underdevelopment, but remained […]
(CureDuchenne letter to Anthem dated March 14) CureDuchenne believes that all those with Duchenne that have a treatment option available to them should have access to the drug. Our heart […]
